Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934276 | 0.89 | CASP3 (0.65) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL23923268 | 0.89 | CASP3 (0.67) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL27100046 | 0.82 | ALOX5 (0.49) | CASP3ALOX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23934209 | 0.82 | RXFP1 (0.47) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL6265840 | 0.80 | CASP3 (0.72) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL23934210 | 0.79 | KMT2A (0.51) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL23934221 | 0.79 | CASP3 (0.60) | CASP3MEN1KMT2A | |
| SCHEMBL27099940 | 0.77 | ALOX5 (0.43) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL23934277 | 0.77 | KMT2A (0.49) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL9167111 | 0.76 | ALOX5 (0.75) | ALOX5MEN1KMT2ASMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | XAVIER UNIVERSITY OF LOUISIANA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | XAVIER UNIVERSITY OF LOUISIANA | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | RPS6KA6, RPS6KA1, RPS6KA3 | CASP3 3051/4885CASP2 3788/4885CASP7 3432/4885 |
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | RPS6KA6, RPS6KA1, RPS6KA3 | CASP3 3051/4885CASP2 3788/4885CASP7 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.